Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome
Low-dose methotrexate is widely used in mycosis fungoides and Sézary syndrome, but few studies have evaluated this treatment. The aim of this study was to evaluate the benefit/risk ratio of this regimen on skin lesions. A retrospective survey of a series of patients treated for mycosis fungoides or...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Society for Publication of Acta Dermato-Venereologica
2021-02-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3719
|
id |
doaj-7f859c2c08154f2ba88334cf1391545d |
---|---|
record_format |
Article |
spelling |
doaj-7f859c2c08154f2ba88334cf1391545d2021-02-05T11:30:15ZengSociety for Publication of Acta Dermato-VenereologicaActa Dermato-Venereologica0001-55551651-20572021-02-011012adv0038410.2340/00015555-37195965Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary SyndromeFawaz Alenezi0Céline GirardDidier BessisBernard GuillotAurélie Du-ThanhOlivier Dereure Department of Dermatology, University of Montpellier and INSERM U1058 Low-dose methotrexate is widely used in mycosis fungoides and Sézary syndrome, but few studies have evaluated this treatment. The aim of this study was to evaluate the benefit/risk ratio of this regimen on skin lesions. A retrospective survey of a series of patients treated for mycosis fungoides or Sézary syndrome with low-dose methotrexate and followed for at least one year in a tertiary referral centre was performed. From a total of 48 patients, complete response and partial response were achieved in 10 (21%) and 25 (52%) patients, respectively, with no significant difference in response rates between mycosis fungoides and Sézary syndrome. Of the responders, 20 out of 35 (57%) relapsed after a median time of 11 months. Forty-four of the total of 48 patients discontinued methotrexate, mainly due to primary or secondary failure and/or limiting toxicity (9 patients). Overall, the benefit/risk ratio of low-dose methotrexate in mycosis fungoides and Sézary syndrome appears favorable and this treatment remains a valid option in mycosis fungoides/Sézary syndrome. However, its activity is limited in duration and significant toxicity may occur in some patients. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3719 mycosis fungoides sézary syndrome methotrexate benefit/risk |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fawaz Alenezi Céline Girard Didier Bessis Bernard Guillot Aurélie Du-Thanh Olivier Dereure |
spellingShingle |
Fawaz Alenezi Céline Girard Didier Bessis Bernard Guillot Aurélie Du-Thanh Olivier Dereure Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome Acta Dermato-Venereologica mycosis fungoides sézary syndrome methotrexate benefit/risk |
author_facet |
Fawaz Alenezi Céline Girard Didier Bessis Bernard Guillot Aurélie Du-Thanh Olivier Dereure |
author_sort |
Fawaz Alenezi |
title |
Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome |
title_short |
Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome |
title_full |
Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome |
title_fullStr |
Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome |
title_full_unstemmed |
Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome |
title_sort |
benefit/risk ratio of low-dose methotrexate in cutaneous lesions of mycosis fungoides and sézary syndrome |
publisher |
Society for Publication of Acta Dermato-Venereologica |
series |
Acta Dermato-Venereologica |
issn |
0001-5555 1651-2057 |
publishDate |
2021-02-01 |
description |
Low-dose methotrexate is widely used in mycosis fungoides and Sézary syndrome, but few studies have evaluated this treatment. The aim of this study was to evaluate the benefit/risk ratio of this regimen on skin lesions. A retrospective survey of a series of patients treated for mycosis fungoides or Sézary syndrome with low-dose methotrexate and followed for at least one year in a tertiary referral centre was performed. From a total of 48 patients, complete response and partial response were achieved in 10 (21%) and 25 (52%) patients, respectively, with no significant difference in response rates between mycosis fungoides and Sézary syndrome. Of the responders, 20 out of 35 (57%) relapsed after a median time of 11 months. Forty-four of the total of 48 patients discontinued methotrexate, mainly due to primary or secondary failure and/or limiting toxicity (9 patients). Overall, the benefit/risk ratio of low-dose methotrexate in mycosis fungoides and Sézary syndrome appears favorable and this treatment remains a valid option in mycosis fungoides/Sézary syndrome. However, its activity is limited in duration and significant toxicity may occur in some patients. |
topic |
mycosis fungoides sézary syndrome methotrexate benefit/risk |
url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3719
|
work_keys_str_mv |
AT fawazalenezi benefitriskratiooflowdosemethotrexateincutaneouslesionsofmycosisfungoidesandsezarysyndrome AT celinegirard benefitriskratiooflowdosemethotrexateincutaneouslesionsofmycosisfungoidesandsezarysyndrome AT didierbessis benefitriskratiooflowdosemethotrexateincutaneouslesionsofmycosisfungoidesandsezarysyndrome AT bernardguillot benefitriskratiooflowdosemethotrexateincutaneouslesionsofmycosisfungoidesandsezarysyndrome AT aurelieduthanh benefitriskratiooflowdosemethotrexateincutaneouslesionsofmycosisfungoidesandsezarysyndrome AT olivierdereure benefitriskratiooflowdosemethotrexateincutaneouslesionsofmycosisfungoidesandsezarysyndrome |
_version_ |
1724283737669107712 |